NF-kappaB in pathogenesis and therapy of head and neck cancer

$717,119ZIAFY2019DCNIH

National Institute On Deafness And Other Communication Disorders

Investigators

Linked publications & trials

Paper 36831373 Paper 35176168 Paper 32002309 Paper 31266830 Paper 30420444 Paper 30380422 Paper 30288354 Paper 30058293 Paper 29959199 Paper 29921694 Paper 28528867 Paper 28295216 Paper 28039268 Paper 27215705 Paper 27208423 Paper 27132513 Paper 27076449 Paper 26690220 Paper 26388988 Paper 26351353 Paper 25977343 Paper 25736767 Paper 25733706 Paper 25724523 Paper 25631445 Paper 25431358 Paper 24715579 Paper 24258200 Paper 24219320 Paper 24177052 Paper 23455325 Paper 22791234 Paper 22641218 Paper 22586569 Paper 22158872 Paper 21933882 Paper 21750205 Paper 21576089 Paper 20533398 Paper 20371694 Paper 19789307 Paper 19570715 Paper 19351843 Paper 18684839 Paper 18645005 Paper 18593997 Paper 17405170 Paper 17317814 Paper 17237265 Paper 17030407 Paper 16432158 Paper 16368071 Paper 16103054 Paper 15989711 Paper 15868906 Paper 15824140 Paper 15623651 Paper 15608421 Paper 15564832 Paper 15374962 Paper 15221009 Paper 15035284 Paper 15014005 Paper 14551747 Paper 12706701 Paper 12536197 Paper 11479233 Paper 11406555 Paper 11297272 Paper 11157034 Paper 11084634 Paper 10928984 Paper 10918606

Abstract

As part of The Cancer Genome Atlas group characterizing head and neck cancer, we have identified components of the classical and alternative NF-kB, PI3K-mTOR, and Notch pathways as candidate genetic drivers for aberrant NF-kB activation and defects in death signaling. A clinical trial with PI3K-mTOR inhibitor rapamycin has completed accrual and published. A multi-center trial targeting IAPs in the classical TNF-NF-kB pathway in combination with re-irradiation has been approved and opened. Studies using a genome wide RNAi screen employing NF-kB reporter lines have identified potential drug targets promoting NF-kB activation, under investigation.

View original record on NIH RePORTER →